Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
New 'People We Meet on Vacation' trailer teases Poppy and Alex romance: Everything we know about the new Netflix movie - 2South Korea president says Iran war shows the need to ditch ‘extremely risky’ fossil fuels
- 3Abbott issues US device correction for some glucose monitors over faulty readings risk
- 4'Euphoria' Season 3 trailer includes Eric Dane's final appearance, Jacob Elordi and Sydney Sweeney at the altar and Zendaya's 'Breaking Bad' era
- 5Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
- Saturn shines with the waxing moon at sunset on Nov. 29
- The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
- Muslim nations condemn new Israeli death penalty law
- Which European countries have mandatory or voluntary military service
- Vacuum Cleaners That Are Not difficult To Use For Home
- Dominating the Art of Composing: Creator Bits of knowledge
- Activists: Venezuela released just nine prisoners despite promise
- Transcript: NASA's Jared Isaacman on "Face the Nation with Margaret Brennan," April 5, 2026
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
